🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against drug-resistant strains of the infection, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are escalating globally, with data suggesting over 82 million infections annually. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Receive Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the American regulatory agency in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This approval represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Results and Worldwide Availability

As per results detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which uses a dual-drug approach. The research enrolled over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to license and sell the drug in numerous regions with limited resources.

Doctors directly involved have expressed optimism. Having a easy-to-administer therapy such as this is hailed as a "revolutionary step" for managing the epidemic. This is deemed vital to alleviate the strain of the infection for patients and to stop the proliferation of untreatable gonorrhoea globally.